NATURIMMUN (317013)

  https://cordis.europa.eu/project/id/317013

  FP7 (2007-2013)

  Natural Killer Cell-Based Anti-Cancer Immunotherapies: Research training in molecular medicine and biotechnology business

  Marie-Curie Action: "Initial Training Networks" (FP7-PEOPLE-2012-ITN)

  inflammatory diseases  ·  genetic engineering  ·  stem cells  ·  oncology  ·  immunotherapy

  2012-10-01 Start Date (YY-MM-DD)

  2016-09-30 End Date (YY-MM-DD)

  € 3,526,286 Total Cost


  Description

In the research part we will deal with the basic principles of the innate immune defense used to control tumors and viral infections with a focus on NK and NK/T cells, including analysis of NK receptor genomics/epigenetics, gene polymorphisms/disease linkage, differentiation of hitherto unrecognized NK cell subpopulations and novel ligands for NK receptors exposed by tumor and/or virally infected cells. We will investigate the mechanisms installed by tumors and viruses to avoid or subvert immune defenses. This will include the investigation of the role of NK/T cell subpopulations in the defense against tumors and infections by herpes virus family members, some being involved in tumor formation, in the development of inflammatory diseases and/or constituting a frequent complication during tumor therapy. The project will support anti-tumor and anti-viral therapies by developing novel technology for NK cell generation from cord blood stem cells for NK cell infusions in patients, by genetic engineering of NK cells and by using NK receptors and their ligands to develop novel reagents for amplifying anti-tumor and -viral activities of NK/T cells. It will further undertake basic studies on the potential of the newly emerging iPS cell technology for reconstituting immune systems including NK cells in patients with hematologic cancers. All students of this ITN will be trained in state-of-the-art immunotechnology including wider aspects of molecular medicine at the individual partner universities. An exchange of students between the different partners will be organized to ensure that every participant will be trained in several laboratories/universities with different expertise. It will further include network-wide training modules with cutting-edge lectures of internationally recognized research experts in the field, state-of-the-art seminars in the front-line technologies used in this project as well as courses in genome-wide bioinformatics, business and patent rights.


  Complicit Organisations

1 Israeli organisation participates in NATURIMMUN.

Country Organisation (ID) VAT Number Role Activity Type Total Cost EC Contribution Net EC Contribution
Spain UNIVERSIDAD POMPEU FABRA (999867077) ESQ5850017D participant HES € 0 € 226,681 € 0
Austria MEDIZINISCHE UNIVERSITAET WIEN (999989976) ATU57469858 participant HES € 0 € 889,734 € 0
United Kingdom THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE (999977172) GB823847609 participant HES € 0 € 285,056 € 0
Netherlands GLYCOSTEM-THERAPEUTICS B.V. (991066073) NL817989481B01 participant PRC € 0 € 236,861 € 0
Germany MILTENYI BIOTEC GMBH (999549305) DE121982110 participant PRC € 0 € 222,068 € 0
Germany MEDIZINISCHE HOCHSCHULE HANNOVER (999878426) DE115650503 coordinator HES € 0 € 450,214 € 0
Germany AFFIMED THERAPEUTICS AG (953152362) nan participant PRC € 0 € 190,800 € 0
France INSTITUT PASTEUR (999993080) FR65775684897 participant REC € 0 € 515,197 € 0
Israel THE HEBREW UNIVERSITY OF JERUSALEM (999975038) IL500701610 participant HES € 0 € 224,613 € 0
United Kingdom UCL Elizabeth Garrett Anderson Institute for Women’s Health (888898146) MISSING participant HES € 0 € 285,056 € 0
United Kingdom KING'S COLLEGE LONDON (999981052) GB627403551 participant HES € 0 € 0 € 0